Board-certified ophthalmologist and vitreoretinal surgeon serving as President and CEO of the Centers for Advanced Surgical Exploration (CASExGLOBAL) and founder of Erie Retina Research — a clinical research organization offering cutting-edge surgical and pharmaceutical ophthalmic research. His research interests span age-related macular degeneration, diabetic eye diseases, complex surgical techniques, and practice management efficiency.

Dr. Almeida has served as principal investigator on 75+ clinical trials at Erie Retina Research, ranging from preclinical to Phases 1 through 4. He sponsors new clinical trials utilizing the ClinOmicsAI platform to identify biomarkers of retinal disease and evaluate individual patient responses through molecular proteomic signatures. He has published over 200 peer-reviewed articles, delivered more than 250 national and international conference and keynote presentations, and was recently selected for Drivers of Change: The Ophthalmologist Power List — highlighting the 50 most influential figures shaping the future of eye care.

• The Ophthalmologist Drivers of Change Power List Top 50
• 200+ peer-reviewed publications · 250+ conference and keynote presentations
• Numerous awards from the American Society of Retina Specialists and the American Academy of Ophthalmology
• BS (Honors), University of Toronto · PhD (Pharmaceutical Drug Research), University of Szeged · MBA (Healthcare Management), The George Washington University · MD & Ophthalmology Residency, Queen's University · Vitreoretinal Disease & Surgery Fellowship, University of Iowa

Directs the Molecular Surgery Program at Stanford, applying high-throughput proteomics, genomics, and phenomics to identify and target the molecules driving eye disease. His research team created the TEMPO precision health tool — integrating human proteomics with single-cell gene expression to map molecular pathways active in living humans. The lab leverages structural biology, medicinal and peptide chemistry, genetics, and AI bioinformatics to advance drug discovery and development.

On the innovation side, Dr. Mahajan holds numerous patents and has successfully licensed drugs from his laboratory to industry. He advises startups and major pharmaceutical firms on clinical trial design, biomarker discovery and validation, FDA regulatory strategy, drug repurposing, and development pathways from preclinical studies through first-in-human trials. His expertise spans multi-modal data integration and translational medicine frameworks that bridge human-tissue proteomics to actionable therapeutics — translating discoveries into clinical trials at Stanford and through the founding of biomedical companies, including ClinOmicsAI.

• Board of Scientific Counselors, National Eye Institute (NIH)
• 250+ peer-reviewed publications
• BS, UC Berkeley · MD/PhD, UC Irvine (Medical Scientist Training Program)
• Ophthalmology Residency, UCLA · Vitreoretinal Fellowship, University of Iowa